SLC22A2 and chronic myelogenous leukemia, BCR-ABL1 positive: In the current study, we investigated the relationships between trough plasma concentrations of bosutinib and serum creatinine values and assessed the effects of the SLC22A2 808G>T polymorphism in patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) receiving bosutinib therapy.